FDA Approves RefluxStop Implant

What Is RefluxStop and How Does It Treat GERD?

The FDA granted premarket approval to the RefluxStop device and its deployment tool on August 20. The approved system is intended to treat acid and non-acid reflux in people diagnosed with gastroesophageal reflux disease, or GERD. Unlike devices that encircle the lower esophagus, RefluxStop is positioned outside the food passageway and is designed to support the anatomy of the gastroesophageal junction.

GERD develops when stomach contents repeatedly move into the esophagus, potentially causing heartburn, regurgitation, inflammation and complications such as esophageal narrowing or Barrett's esophagus. Proton pump inhibitors reduce acid production but do not physically prevent reflux. Surgery may be considered when objectively confirmed GERD remains troublesome despite appropriate medical care or when a well-informed patient prefers a procedural option.

What Evidence Supported the FDA Approval?

The pivotal study enrolled adults with chronic typical GERD symptoms, daily proton pump inhibitor use and abnormal 24-hour pH monitoring. Among the 44 participants who completed five-year follow-up, the published report described a 90% median improvement in the total GERD Health-Related Quality of Life score. Regular proton pump inhibitor use was reported in one of 47 participants included in the medication analysis.

The FDA summary reported no serious or non-serious adverse events attributed directly to the device during the pivotal investigation, although procedure-related serious events occurred and required treatment. The absence of a randomized comparison group and the small study population limit conclusions about how RefluxStop compares with fundoplication, magnetic sphincter augmentation or optimized medical therapy. A subsequent systematic review also identified device-related complications such as migration, slippage and gastric penetration, reinforcing the need for longer-term evidence.

Who Might Be Considered for RefluxStop Treatment?

Symptoms alone are not enough to determine whether an implant is appropriate. Evaluation before antireflux surgery commonly includes endoscopy, ambulatory reflux monitoring and, when indicated, esophageal manometry to confirm reflux and exclude disorders that may imitate GERD. Alarm symptoms such as difficulty swallowing, gastrointestinal bleeding, unexplained weight loss or persistent vomiting require prompt medical evaluation.

RefluxStop remains an operation, with risks associated with anesthesia, hiatal repair, infection, bleeding, swallowing problems, reoperation and device complications. FDA documentation lists known sensitivity to device materials among the contraindications. The required REVEAL postmarket study is expected to enroll 200 patients and follow them for five years, tracking serious events, acid exposure, quality of life, medication use and the ability to belch.